Shares of Zydus Lifesciences jumped around 6% after the company announced that its board of directors will meet on May 19 (Tuesday) to consider a buyback of shares. The pharma company also announced the acquisition of US-based cancer drug-maker Assertio for $166.4 million.
Zydus Lifesciences shares climbed to an intraday high of Rs 993.80 on Thursday. The stock is up about 8% over the past month and 10% over the past year. Over the longer term, Zydus Lifesciences has delivered a 93% return in three years and nearly 61% over five years.
